Skip Navigation

Cardiovascular Research 1999 43(3):628-638; doi:10.1016/S0008-6363(99)00114-5
© 1999 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Hayward, C. S
Right arrow Articles by Macdonald, P. S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hayward, C. S
Right arrow Articles by Macdonald, P. S
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 1999, European Society of Cardiology

Inhaled nitric oxide in cardiology practice

Christopher S Haywarda,*, Raymond P Kellyb and Peter S Macdonaldb

aDepartment of Cardiac Medicine, National Heart and Lung Institute, Imperial College School of Medicine, London SW3 6LY, UK
bCardiology Department, St Vincent’s Hospital, Darlinghurst, NSW, 2010 Australia

* Corresponding author. Tel.: +44-171-351-8631; fax: +44-171-823-3392 c.s.hayward{at}ic.ac.uk

Inhaled nitric oxide allows selective pulmonary vasodilatation with rapidity of action. It is effective in the acute post-operative management of pulmonary hypertension in cardiac surgical patients and is also valuable in assessing the pulmonary vasodilator capacity in patients with chronic pulmonary hypertension. This review examines the current role of inhaled nitric oxide in cardiac medicine, discussing issues concerning its administration and toxicity, as well as a summary of clinical studies in cardiac patients. New roles, as a modifier of platelet and leukocyte function, post-thrombolysis and following lung transplantation are described. New agents and alternative therapies, which prolong pulmonary activity, are also discussed.

KEYWORDS NO, Nitric oxide; INO, Inhaled nitric oxide; ppm, Parts per million, cGMP, Guanosine 3',5'-cyclic monophosphate; GC, Guanylate cyclase; MetHb, Methaemoglobin; NOHb, Nitrosyl-haemoglobin; ARDS, Adult respiratory distress syndrome; PVR, Pulmonary vascular resistance; LVAD, Left ventricular assist device


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.